Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy (vol 52, pg 298, 2022)

被引：0
|
作者：
Maesaka, K.
Sakamori, R.
Yamada, R.
Tahata, Y.
Imai, Y.
Ohkawa, K.
机构：
来源：
HEPATOLOGY RESEARCH | 2022年 / 52卷 / 07期
关键词：
D O I：
10.1111/hepr.13775
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：659 / 659
页数：1
相关论文
共 50 条
  • [31] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
    Hayakawa, Yuka
    Tsuchiya, Kaoru
    Kurosaki, Masayuki
    Yasui, Yutaka
    Kaneko, Shun
    Tanaka, Yuki
    Ishido, Shun
    Inada, Kento
    Kirino, Sakura
    Yamashita, Koji
    Nobusawa, Tsubasa
    Matsumoto, Hiroaki
    Kakegawa, Tatsuya
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Nakanishi, Hiroyuki
    Itakura, Jun
    Takahashi, Yuka
    Asahina, Yasuhiro
    Okamoto, Ryuichi
    Izumi, Namiki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 392 - 402
  • [32] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
    Yuka Hayakawa
    Kaoru Tsuchiya
    Masayuki Kurosaki
    Yutaka Yasui
    Shun Kaneko
    Yuki Tanaka
    Shun Ishido
    Kento Inada
    Sakura Kirino
    Koji Yamashita
    Tsubasa Nobusawa
    Hiroaki Matsumoto
    Tatsuya Kakegawa
    Mayu Higuchi
    Kenta Takaura
    Shohei Tanaka
    Chiaki Maeyashiki
    Nobuharu Tamaki
    Hiroyuki Nakanishi
    Jun Itakura
    Yuka Takahashi
    Yasuhiro Asahina
    Ryuichi Okamoto
    Namiki Izumi
    Investigational New Drugs, 2022, 40 : 392 - 402
  • [33] Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
    Sang, Y. B.
    Lee, C. R.
    Kim, S-G.
    Lee, B.
    Kim, C.
    Chon, H. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1549 - S1550
  • [34] Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series
    Sakaguchi, Koki
    Satoh, Tatsunori
    Kawaguchi, Shinya
    Aoyama, Takuya
    Asahara, Kazuhisa
    Endo, Shinya
    Shirane, Naofumi
    Kanemoto, Hideyuki
    Oba, Noriyuki
    Ohno, Kazuya
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (03) : 515 - 522
  • [35] Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Yumita, Sae
    Ogasawara, Sadahisa
    Nakagawa, Miyuki
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kogure, Tadayoshi
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Inoue, Masanori
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Kato, Jun
    Kato, Naoya
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [36] Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study
    Ueno, Masaki
    Kosaka, Hisashi
    Iida, Hiroya
    Ida, Yoshiyuki
    Aoi, Kazunori
    Mori, Haruki
    Miyamoto, Atsushi
    Nishida, Yuko
    Hayami, Shinya
    Kawai, Manabu
    Kaibori, Masaki
    ONCOLOGY, 2023, 101 (09) : 565 - 574
  • [37] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    JAMA NETWORK OPEN, 2021, 4 (04)
  • [38] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Mah I Kan Changez
    Maimoona Khan
    Muhammad Uzair
    Muhammad Fawad Tahir
    Maryam Mohsin
    Amna Faiyaz Hussain
    Vania Saqib
    Muhammad Khizer Molani
    Aisha Habib Ahmed
    Saad Khalid
    Journal of Gastrointestinal Cancer, 2024, 55 : 467 - 481
  • [39] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
    Chon, Young Eun
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kang, Beodeul
    Ha, Yeonjung
    Kim, Do Young
    Hwang, Seong Gyu
    Chon, Hong Jae
    Kim, Beom Kyung
    CANCER MEDICINE, 2023, 12 (03): : 2731 - 2738
  • [40] Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma
    Takada, Hitomi
    Yamashita, Koji
    Osawa, Leona
    Komiyama, Yasuyuki
    Muraoka, Masaru
    Suzuki, Yuichiro
    Sato, Mitsuaki
    Kobayashi, Shoji
    Yoshida, Takashi
    Takano, Shinichi
    Maekawa, Shinya
    Enomoto, Nobuyuki
    HEPATOLOGY RESEARCH, 2024, 54 (02) : 162 - 173
12345